Navigation Links
Neurocrine Announces Work Force Restructuring
Date:5/5/2009

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today staff reductions of approximately 60 employees, as a part of its restructuring program to focus the Company's efforts on its clinical programs and pre-clinical development leads. Following these reductions, Neurocrine will have approximately 60 employees.

"We are disappointed that we have to make this painful decision that will have such an effect on so many of our employees and their families. Our employees have always shown the highest level of commitment and displayed incredible passion for the efforts around drug discovery; however, in order to meet our clinical goals, we have to refocus our resources. I want to sincerely thank the departing employees for their efforts and loyalty, these are highly talented people and I am sure they are going to find continued success in their careers," said Kevin C. Gorman President & CEO. "We will maintain our efforts on elagolix, move our VMAT2 program into the clinic, and focus on the other high value assets. We continue to conservatively manage our cash resources while advancing our pipeline."

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2008. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
4. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
5. Neurocrine Biosciences Reports Third Quarter 2008 Results
6. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
7. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
9. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
10. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
11. Neurocrine Biosciences Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016  Bayer today announced that ... Stivarga ® (regorafenib) tablets for the treatment ... met its primary endpoint of a statistically significant ... evaluated the efficacy and safety of regorafenib in ... treatment with sorafenib. The safety and tolerability were ...
(Date:5/4/2016)... May 4, 2016 According to ... "Metabolomics Market - Global Industry Analysis, Size, Share, Growth, ... is anticipated to expand at a CAGR of 17.1% ... by 2024. Metabolomics is the extensive study ... biofluids, tissues or organisms. Together, these small molecules and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, a ... help treat hormonal and stress related hair loss. With patent-pending formulas for both ... key opinion leaders in the medical and salon channels nationwide. , Dermatologists, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Morf ... and compliance training platform on mobile devices, today released a new interactive ... for Medical Devices. The course is essential for owners or operators of places ...
Breaking Biology Technology:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):